Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.43 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581161 | 0.81 | BCL2 (0.42) | HMGB1CXCL12BCL2 | |
| SCHEMBL2013978 | 0.79 | HTT (0.50) | PAX8KDM4EL3MBTL1CTSB | |
| SCHEMBL3588090 | 0.77 | PIK3CD (0.50) | PAX8EGLN1KDM4EL3MBTL1 | |
| SCHEMBL3581164 | 0.77 | NPC1 (0.47) | EGLN1KDM4EL3MBTL1 | |
| SCHEMBL9749183 | 0.76 | BCL2 (0.54) | KDM4EHMGB1CXCL12BCL2 | |
| SCHEMBL24716136 | 0.75 | PAX8 (0.57) | PAX8KDM4EL3MBTL1CTSB | |
| SCHEMBL2015831 | 0.75 | L3MBTL1 (0.60) | PAX8KDM4EL3MBTL1CTSB | |
| SCHEMBL2014457 | 0.75 | ALOX12 (0.64) | KDM4EL3MBTL1 | |
| SCHEMBL2518133 | 0.75 | PAX8 (0.59) | PAX8KDM4EL3MBTL1CTSB | |
| SCHEMBL6480271 | 0.73 | EGLN1 (0.43) | PAX8EGLN1KDM4ECTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2033952-B1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | SHIONOGI & CO (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-7759372-B2 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| EP-2045242-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | Shionogi&Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-2033952-A1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | Shionogi&Co., Ltd. (JP) | 2009-03-11 | — | — | EP | disclosed |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2008-11-13 | — | — | US | disclosed |
| EP-1375486-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1541558-B1 | HETEROCYCLIC COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-20060293334-A1 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | FUJI MASAHIRO | 2006-12-28 | — | — | US | disclosed |
| US-20060128669-A1 | Heterocyclic compounds having inhibitory activity against hiv integrase | SHIONOGI & CO., LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| CN-1659143-A | Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity | SHIONOGI & CO (JP) | 2005-08-24 | — | — | CN | disclosed |
| EP-1541558-A1 | HETEROCYCLIC COMPOUND HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1375486-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-0362771-B1 | Use of photochromic substances | RODENSTOCK OPTIK G (DE) | 2000-05-31 | — | — | EP | disclosed |
| US-5637709-A | Photochromatic substances | OPTISCHE WERKE G. RODENSTOCK (DE) | 1997-06-10 | — | — | US | disclosed |
| US-5608065-A | ADAMANTANEOSPIRO-HETEROAROMATIC PYRANS | OPTISCHE WERKE G. RODENSTOCK (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0362771-A1 | Photochromic substances | Optische Werke G. Rodenstock (DE) | 1990-04-11 | — | — | EP | disclosed |
| WO-1990003379-A1 | PHOTOCHROMIC SUBSTANCES | OPTISCHE WERKE G. RODENSTOCK (DE) | 1990-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | PAX8 3886/4885EGLN1 3314/4885KDM4E 1722/4885 |
| US-20080280849-A1 | Synergic Combinations Comprising a Quinoline Compound and Other Hiv Infection Therapeutic Agents | CTSL, CDKL1, QTRT2 | PAX8 3628/4885EGLN1 2104/4885KDM4E 2169/4885 |
| US-20060293334-A1 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | ZC3HAV1, INTS9, PRDM9 | PAX8 3019/4885EGLN1 2402/4885KDM4E 220/4885 |
| US-20060128669-A1 | Heterocyclic compounds having inhibitory activity against hiv integrase | CYP3A7, CDK7, CYP2A7 | PAX8 3886/4885EGLN1 3314/4885KDM4E 1722/4885 |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | DUT, PNP, INMT | PAX8 3635/4885EGLN1 1824/4885KDM4E 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.